AMD Macular Degeneration
Conditions
Interventions
All participants of the study will receive daily oral 50 mg zinc as zinc
sulfate and 1 mg copper as cupric sulphate for 3 months.
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Men and women >= 50 years of age. • AMD patients previously included in the EUGENDA database. • Previously genotyped for Y402H (rs1061170) gene variation (from EUGENDA database). • Patients with extensive small drusen, intermediate drusen, large drusen, advanced neovascular AMD without neovascular activity in one or both eyes or geographic atropy in one or both eyes. • Informed consent.
Exclusion criteria
Exclusion criteria: • Active leakage from CNV due to AMD. • Ongoing anti/VEGF treatment. • Ongoing infection. • Subretinal hemorrhages. • History of any vitreous hemorrage within 12 weeks. • Other ocular disorders that may confound the interpretation of the study results. • Systemic or local steroid treatment within the last three months. • Use of any antibiotica. • Prolonged use of diuretics. • Supplemental use of iron (38-65 mg/day of elemental iron). • Use of zink and vitamin supplements one month prior to the study. • Systhemic diseases that may influence complement levels (atypical haemolytic uraemic syndrome (aHUS), membranoproliferative glomerulonephritis type 2 (MG2)).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the serum level of activation fragment C3d and complement component C3, C3d/C3 ratio will be calculated. This ratio is the activity marker of alternative complement pathway. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is the correlation between this supposed drop in serum level C3d and Y402H polymorphism status in CFH. | — |
Countries
Netherlands
Outcome results
None listed